CD274 and neoplasm: Currently, several biomarkers, such as PD-L1 expression, tumor mutation burden [8], virus infection [9], and genetic mutations within cancer cells [10], have been investigated to determine if they are associated with the treatment efficacy of PD-1/PD-L1 inhibitors.